All In Biotech

Free tool

FAERS Monitor: Hadlima

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761059 or its brand name (Hadlima, Adalimumab-Bwwd). Reports on generic versions are filed under their own applications.

Reports

10

Serious

4

40% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug hypersensitivity2
  • injection site pain2
  • tachypnoea2
  • drug ineffective1
  • general physical health deterioration1
  • headache1
  • influenza like illness1
  • pain1
  • rash pruritic1
  • rash pustular1
  • tachycardia1
  • therapy interrupted1
  • uveitis1

Reports by year received

View as table
YearReports
20245
20253
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
tachypnoea2309.689.6345
rash pustular1288.845.071
uveitis1155.124.238
rash pruritic138.86.09
therapy interrupted129.44.66
influenza like illness125.64.05
tachycardia123.73.75
drug hypersensitivity221.76.322
general physical health deterioration118.22.84
injection site pain213.74.013
pain13.40.50
headache13.40.50
drug ineffective11.60.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.